Programmable DNA Hydrogels with Zinc Oxide Nanoparticles and Cisplatin for Diagnosis and Treatment of Oral Squamous Cell Carcinoma

This study investigates DNA hydrogels loaded with Zinc Oxide Nanoparticles (ZnO NPs) and Cisplatin for the diagnosis and treatment of Oral Squamous Cell Carcinoma (OSCC). In vitro and in vivo results show enhanced drug delivery, reduced side effects, and improved cancer diagnosis, highlighting the potential of DNA hydrogels as a promising approach for OSCC treatment.

Abstract

This study explores the potential of DNA hydrogels as a novel approach for diagnosing and treating Oral Squamous Cell Carcinoma (OSCC). In the experiment, DNA hydrogels are synthesized and loaded with Zinc Oxide Nanoparticles (ZnO NPs) and Cisplatin. In vitro experiments evaluated drug delivery efficacy and the effect on cancer cell viability. In vivo, studies used mice models to assess the therapeutic potential and antimicrobial activity of the DNA hydrogels. Results demonstrate that DNA hydrogels significantly improve the delivery of Cisplatin to cancer cells, potentially allowing for lower drug doses and reduced side effects. The combination of Cisplatin and ZnO NPs show the most potent antibacterial effect against bacterial strains associated with OSCC. Analysis indicates that ZnO NPs within the hydrogels improve the efficacy of contrast agents, facilitating earlier and more accurate tumor diagnosis. The findings highlight that DNA hydrogels loaded with therapeutic agents can enhance drug delivery and reduce side effects, while ZnO NPs improve tumor diagnosis. DNA hydrogels may represent a promising patient-centric approach for more effective OSCC treatment.